{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:27:38Z","timestamp":1773296858185,"version":"3.50.1"},"reference-count":24,"publisher":"Tech Science Press","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["oncol res"],"published-print":{"date-parts":[[2019,6,21]]},"abstract":"<jats:p>Apatinib is an oral TKI with antiangiogenic properties, and it is currently approved for the treatment of advanced gastric cancer in China. This agent has also been tested in other human solid tumors, including non-small cell lung cancer (NSCLC). Since the combination of chemotherapy\n and an antiangiogenic agent has been shown to be a feasible strategy in NSCLC, it is conceivable that a similar approach combining apatinib with chemotherapy may yield clinical activity. With this in mind, we investigated the efficiency of apatinib in combination with pemetrexed or docetaxel\n in advanced NSCLC. We treated a total of 20 patients with metastatic NSCLC adenocarcinoma with apatinib in combination with either pemetrexed or docetaxel from January 2016 to March 2017. The performance status of these patients was 0 or 1. All of these patients had been previously treated\n with two or more lines of treatment and had experienced disease progression prior to study enrollment. The overall objective response rate (ORR) was 30%, with 6 patients who had partial response (PR), 10 patients who had stable disease (SD), and 4 patients who had progressive disease (PD).\n The main adverse events were skin rash, hypertension, palmar\u2010plantar erythrodysesthesia syndrome, diarrhea, and fatigue. Nearly 30% of patients required interruption of treatment as a result of toxicity. Our study demonstrated that apatinib combined with systemic cytotoxic chemotherapy\n has clinical efficacy in patients with disease-refractory metastatic NSCLC and provides evidence for further studies investigating apatinib-based combination regimens.<\/jats:p>","DOI":"10.3727\/096504018x15288447760357","type":"journal-article","created":{"date-parts":[[2018,6,22]],"date-time":"2018-06-22T01:16:03Z","timestamp":1529630163000},"page":"635-641","source":"Crossref","is-referenced-by-count":19,"title":["Apatinib Plus Chemotherapy Shows Clinical Activity in Advanced NSCLC: A Retrospective Study"],"prefix":"10.32604","volume":"27","author":[{"given":"Jing","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Lymphoma in Hubei Cancer Hospital, Wuhan City, Hubei Province, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu Yong","family":"Li","sequence":"additional","affiliation":[{"name":"Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan City, Hubei Province, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing Bo","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of People\u2019s Hospital of Yicheng, Xiang yang City, Hubei Province, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"De","family":"Wu","sequence":"additional","affiliation":[{"name":"Centre of Molecular Diagnosis in Hubei Cancer Hospital, Wuhan City, Hubei Province, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of 1st Division of Thoracic Tumor in Hubei Cancer Hospital, Wuhan City, Hubei Province, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaobing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of 1st Division of Thoracic Tumor in Hubei Cancer Hospital, Wuhan City, Hubei Province, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"17807","reference":[{"issue":"38","key":"b1","doi-asserted-by":"crossref","first-page":"64471","DOI":"10.18632\/oncotarget.16293","article-title":"Efficacy and safety of Apatinib in stage IV sarcomas: Experience of a major sarcoma center in China","volume":"8","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"b2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1470-2045(13)70586-2","article-title":"Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): A phase 3, double-blind, randomised controlled trial","volume":"15","year":"2014","journal-title":"Lancet Oncol."},{"issue":"9944","key":"b3","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): A multicentre, double-blind, randomised phase 3 trial","volume":"384","year":"2014","journal-title":"Lancet"},{"issue":"19","key":"b4","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1200\/JCO.2014.59.4424","article-title":"BEYOND: A randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin\/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small cell lung cancer","volume":"33","year":"2015","journal-title":"J Clin Oncol."},{"issue":"5","key":"b5","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1470-2045(15)70127-0","article-title":"Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): A randomised, double-blind, multicentre, phase 3 study","volume":"16","year":"2015","journal-title":"Lancet Oncol."},{"issue":"11","key":"b6","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial","volume":"15","year":"2014","journal-title":"Lancet Oncol."},{"issue":"26","key":"b7","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2013.48.8585","article-title":"Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: Results from a randomized, placebo-controlled, parallel-arm, phase II trial","volume":"31","year":"2013","journal-title":"J Clin Oncol."},{"issue":"13","key":"b8","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","article-title":"Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction","volume":"34","year":"2016","journal-title":"J Clin Oncol."},{"issue":"20","key":"b9","doi-asserted-by":"crossref","first-page":"7981","DOI":"10.1158\/0008-5472.CAN-10-0111","article-title":"Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters","volume":"70","year":"2010","journal-title":"Cancer Res."},{"issue":"37","key":"b10","doi-asserted-by":"crossref","first-page":"59236","DOI":"10.18632\/oncotarget.10985","article-title":"Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET\/Src signaling pathway","volume":"7","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"b11","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1358\/dot.2015.51.4.2320599","article-title":"Apatinib: A promising oral antiangiogenic agent in the treatment of multiple solid tumors","volume":"51","year":"2015","journal-title":"Drugs Today (Barc)"},{"issue":"20","key":"b12","doi-asserted-by":"crossref","first-page":"e3598","DOI":"10.1097\/MD.0000000000003598","article-title":"The use of apatinib in treating nonsmall-cell lung cancer: Case report and review of literature","volume":"95","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"b13","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ctrv.2012.05.003","article-title":"Targeted agents in the third-\/fourth-line treatment of patients with advanced (stage III\/IV) non-small cell lung cancer (NSCLC)","volume":"39","year":"2013","journal-title":"Cancer Treat Rev."},{"key":"b14","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2147\/OTT.S126613","article-title":"Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma","volume":"10","year":"2017","journal-title":"Onco Targets Ther."},{"issue":"15","key":"b15","doi-asserted-by":"crossref","first-page":"e6578","DOI":"10.1097\/MD.0000000000006578","article-title":"A case report of apatinib in treating osteosarcoma with pulmonary metastases","volume":"96","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"b16","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.2147\/OTT.S113435","article-title":"Salvage treatment with apatinib for advanced non-small-cell lung cancer","volume":"10","year":"2017","journal-title":"Onco Targets Ther."},{"key":"b17","first-page":"6075","article-title":"Apatinib for molecular targeted therapy in tumor","volume":"9","year":"2015","journal-title":"Drug Des Devel Ther."},{"issue":"31","key":"b18","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1200\/JCO.2015.61.6870","article-title":"Pseudoprogression and immune-related response in solid tumors","volume":"33","year":"2015","journal-title":"J Clin Oncol."},{"issue":"19","key":"b19","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","year":"2015","journal-title":"N Engl J Med."},{"key":"b20","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.2147\/OTT.S126471","article-title":"Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: A case report","volume":"10","year":"2017","journal-title":"Onco Targets Ther."},{"issue":"31","key":"b21","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2016.68.6931","article-title":"Apatinib in advanced gastric cancer: A doubtful step forward","volume":"34","year":"2016","journal-title":"J Clin Oncol."},{"issue":"31","key":"b22","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1200\/JCO.2016.68.8663","article-title":"Is treatment-emergent toxicity a biomarker of efficacy of apatinib in gastric cancer?","volume":"34","year":"2016","journal-title":"J Clin Oncol."},{"issue":"31","key":"b23","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1200\/JCO.2016.67.3889","article-title":"Problematic analysis and inadequate toxicity cata in phase III apatinib trial in gastric cancer","volume":"34","year":"2016","journal-title":"J Clin Oncol."},{"issue":"6","key":"b24","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.cllc.2015.04.003","article-title":"Preliminary safety, pharmacokinetics, and efficacy of regorafenib, cisplatin, and pemetrexed in patients with advanced nonsquamous non-small-cell lung cancers","volume":"16","year":"2015","journal-title":"Clin Lung Cancer"}],"container-title":["Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.techscience.com\/uploads\/attached\/file\/20220623\/20220623112516_82174.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T21:37:47Z","timestamp":1733521067000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.techscience.com\/or\/v27n6\/48580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,21]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6,21]]}},"alternative-id":["0965-0407(20190621)27:6L.635;1-"],"URL":"https:\/\/doi.org\/10.3727\/096504018x15288447760357","relation":{},"ISSN":["0965-0407"],"issn-type":[{"value":"0965-0407","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6,21]]}}}